BRU · UCB.BR
UCB S.A.
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
Loading market information…
BRU · CYAD.BR · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:16 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Celyad Oncology S.A.’s quoted price sits in the lower half of its reported 52-week range, 67.69% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Celyad Oncology S.A.’s next earnings report is currently expected on Mar 25, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Celyad Oncology S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:06 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| €0.00 |
KEEP COMPARING
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
€227.60+€6.80 (+3.08%)
Financière de Tubize S.A.’s quoted price sits in the upper half of its reported 52-week range, 9.14% below the high.
€28.90+€0.34 (+1.19%)
Lakefront Biotherapeutics’s quoted price sits in the upper half of its reported 52-week range, 5.92% below the high.
€23.40-€0.45 (-1.89%)
Fagron N.V.’s quoted price sits in the upper half of its reported 52-week range, 7.51% below the high.
€16.46+€0.12 (+0.73%)
Ion Beam Applications S.A.’s quoted price sits in the upper half of its reported 52-week range, 7.32% below the high.
$7.95-$0.01 (-0.13%)
AgomAb Therapeutics N.V. American Depositary Shares’s quoted price sits in the lower half of its reported 52-week range, 55.39% below the high.
€3.86+€0.21 (+5.75%)
Hyloris Pharmaceuticals S.A.’s quoted price sits in the lower half of its reported 52-week range, 54.05% below the high.
$0.89-$0.01 (-1.34%)
Nyxoah S.A.’s quoted price sits in the lower half of its reported 52-week range, 85.0% below the high.
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
